generic propranolol canadian pharmacy no prescription

The US Food and Drug Administration’s (FDA’s) review of the biologics license application (BLA) for bimekizumab for the treatment of psoriasis is continuing. A decision on the approval application has been delayed until the third quarter of this year, according to a June 26 announcement by the manufacturer, UCB. The FDA’s decision had been expected by the end of June. […]
» Read more